By Hand Delivery September 14, 2012 Lewis H. Bender Re: Separation AgreementSeparation Agreement • September 20th, 2012 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Massachusetts
Contract Type FiledSeptember 20th, 2012 Company Industry JurisdictionThe purpose of this letter agreement (the “Agreement”) is to set forth the terms of your separation from Interleukin Genetics, Inc. (“Interleukin” or the “Company”). Payment of the Separation Benefit described below is contingent on your agreement to and compliance with the terms of this Agreement, as set forth below.